Compare PROK & PUBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROK | PUBM |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.8M | 303.6M |
| IPO Year | 2021 | 2020 |
| Metric | PROK | PUBM |
|---|---|---|
| Price | $1.88 | $9.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.40 | ★ $12.43 |
| AVG Volume (30 Days) | ★ 1.0M | 591.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $893,000.00 | ★ $282,926,000.00 |
| Revenue This Year | N/A | $3.44 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.54 | $6.15 |
| 52 Week High | $7.13 | $13.26 |
| Indicator | PROK | PUBM |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 66.67 |
| Support Level | $1.71 | $7.92 |
| Resistance Level | $2.58 | $11.08 |
| Average True Range (ATR) | 0.12 | 0.41 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 13.89 | 87.77 |
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.